Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/15/12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
33 |
| 05/14/12 | 8-K | Current report filing |
|
3 | |
| 05/07/12 | UPLOAD | SEC-generated letter |
|
3 | |
| 04/24/12 | DEF 14A | Definitive proxy statements |
|
13 | |
| 04/12/12 | S-1/A | General form of registration statement for all companies including face-amount certificate companies |
|
|
84 |
| 04/11/12 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
13 | |
| 04/06/12 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
57 |
| 03/30/12 | NT 10-K | Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10-KT |
|
2 | |
| 02/23/12 | UPLOAD | SEC-generated letter |
|
3 | |
| 02/22/12 | S-1/A | General form of registration statement for all companies including face-amount certificate companies |
|
113 |
